Cibus US LLC
4025 Sorrento Valley Boulevard
19 articles with Cibus US LLC
Cibus, a leading agricultural biotechnology company, announced the appointment of Rory Riggs, co-founder, and Chairman of Cibus, to serve as Chief Executive Officer.
Cibus Welcomes the European Commission’s Landmark Study on New Genomic Techniques (NGTs) that Includes Cibus’ Gene Editing Technologies
Study Affirms the Potential of NGTs to Significantly Contribute to Agriculture Sustainability, the Key Objectives of the European Green Deal (Farm to Fork), and Makes an Urgent Call for Regulatory Reform
Cibus, a leader in precision gene editing in agriculture, today announced the appointment of Wade King, M.D., as Chief Financial Officer (CFO). Dr. King joins Cibus with over 25 years of experience in both public and private life science companies leading senior strategy, corporate development, finance and investments.
Trial Results Mark a Significant Milestone in the Development of a Trait that Provides Tolerance to White Mold (Sclerotinia) in Canola/Oil Seed Rape Plants
Cibus Applauds the European Food Safety Authority (EFSA) Conclusion that Gene Editing by ODM, SDN-1 and SDN-2 Does Not Pose More Hazards than Conventional Plant Breeding
EFSA scientific opinion represents an important step in Europe’s “Farm to Fork” initiative
Cibus Sharpens Corporate Focus to Concentrate on the Five Major Input and Agronomic Trait Markets in the Five Major High Yielding Crops, Divests its Canola Seed Business
Cibus, a leader in developing trait products for agriculture, announced a sharpened strategic focus.
Trait products largely relate to fungal-disease resistance and herbicide resistance in canola, further bolstering Cibus’ position as a leader in non-GMO input and agronomy traits SAN DIEGO--( BUSINESS WIRE )-- Cibus, a leader in input and agronomy trait products, announced today an additional 12 of its trait products have been designated as non-regulated by the United States Department of Agriculture’s Animal and Plant Health Inspection Service (USDA
Cibus, a pioneer of precision gene editing in agriculture, announced the appointment of former Internal Counsel, Rosa Cheuk Kim, to Vice President, Legal. In her elevated role, Cheuk Kim will oversee all legal activities at Cibus, including intellectual property, contracts and litigation.
USDA-APHIS Confirms Cibus’ Weed Control Traits in Flax and Rice Are Not Regulated Articles Under GMO RULES (7 CFR Part 340)
Cibus, a pioneer in precision gene editing in agriculture, will advance herbicide tolerance traits in rice and flax crops to commercial development following United States Department of Agriculture’s Animal and Plant Health Inspection Service (USDA-APHIS) Biotechnology Regulatory Services (BRS) confirm
Cibus Achieves Critical Milestones for Two New Gene-Edited Traits that Increase Productivity for Rice Farmers
Precision gene-edited traits for one of the world’s largest crops to help reduce farmers’ costs, while improving yield and quality
Traits added in leading crop with precision gene editing and without integration of foreign genetic material to reduce costs, improve yield, and increase environmental health
Further Extends Cibus Intellectual Property for its Precise Gene-Editing Technologies
Cibus, a leader in advanced plant-breeding technologies, today announced it has licensed to Valley Oils Partners certain U.S. rights to cultivate canola with the Cibus ultra-high-oleic oil trait.
Cibus, a leader in advanced plant-breeding technologies, today announced it has postponed plans for an initial public offering.
Cibus Global, Ltd. today announced the launch of its underwritten initial public offering of 6,666,667 shares of its Class A common stock pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission.
Cibus today announced the launch of its new seed brand, Falco™, offering North American canola growers four new canola varieties for the 2019 growing season, with additional varieties planned for next season.
Cibus intends to list its common stock on the Nasdaq Global Market under the trading symbol “CBUS.”
Cibus, a leader in the application of gene editing technologies for directed mutagenesis, announced it has raised $70 million in a Series C funding.